Longevity Health Holdings

Longevity Health Holdings

Founded in 2021 in Palm Beach Gardens, Longevity Health Holdings emerged from a special purpose acquisition company rooted in the biohacking and wellness movement. The entity formally acquired Regenative Medicine, a physician-dispensed nutraceutical business, and Vitramune, a freeze-dried meal-prep line, in separate transactions during 2023. Jonnie Williams — the tobacco-to-supplement entrepreneur — surfaced as the majority financial backer, while CEO Paul Lin and Chief Medical Officer Dr. Terry Grossman shaped the operational thesis around subscription-based wellness protocols. The firm’s deployment model targets direct acquisitions of revenue-generating consumer-health and longevity assets, bypassing traditional venture-stage biotech risk. The portfolio combines Regenative’s network of clinicians dispensing oral supplements with Vitramune’s direct-to-consumer meal plans, creating cross-sell economics between practitioner-recommended nutraceuticals and at-home nutrition. Post-close, the entity disclosed plans for clinic-based concierge longevity centers in Florida — aiming to layer diagnostics, peptides, and hormone optimization onto the existing supplement and meal-prep subscription base. Longevity Health Holdings operates as a publicly listed vehicle but functions internally like a private holding company, with a lean corporate structure centered in South Florida. In January 2024, the firm announced a binding letter of intent to acquire an operating chain of physical longevity clinics in the South Florida market, signaling an intent to anchor recurring clinic revenue alongside the existing product lines. This structure is distinct from both pure-play health-tech startups and traditional healthcare REITs — it stitches together reimbursement-agnostic, cash-pay wellness revenue streams under a single public ticker. The presence of a sole majority sponsor with a history in dietary supplements (Williams previously founded Star Scientific) concentrates governance in a way that mirrors family-office direct investing, despite the publicly traded shell.